Introduction {#Sec1}
============

Gastric cancer is the second most common malignancy globally and the third most common cause of cancer-related deaths in Japan. Despite considerable advances in overall gastric cancer treatment, approaches for the treatment of gastric cancer metastasizing only to the liver have been controversial. Some studies suggest that hepatectomy is effective against gastric cancer with only liver metastasis, with a 5-year overall survival (OS) ranging from 20 to 40% \[[@CR1]--[@CR11]\], whereas results of other studies investigating the benefit of hepatic resection for liver metastasis of gastric cancer were unclear \[[@CR12]--[@CR14]\]. The present study aimed to evaluate the outcomes of surgical treatment for liver metastasis of gastric cancer.

Materials and Methods {#Sec2}
=====================

In this retrospective study, we reviewed the medical records of 10 patients with liver-only metastases of gastric cancer who underwent hepatic resection among 2043 patients with gastric cancer who underwent gastric resection between January and to December 2016 at Toyohashi Municipal Hospital. The study flowchart is presented in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow chart

Inclusion criteria for this study were as follows: (1) histologically confirmed gastric cancer; (2) presence of synchronous or metachronous liver metastasis; and (3) surgical therapy performed between January 1, 1991, and December 31, 2017. Patients with double cancers were excluded. The study was conducted in accordance with the Declaration of Helsinki of 1975, revised in 2000. Clinical and pathological data included sex, age, and information regarding primary gastric cancer and liver metastases. The 14th edition of the Japanese Classification of Gastric Carcinoma was utilized for this study. Data regarding the last follow-up and vital status were collected for all the patients.

Statistical Analysis {#Sec3}
--------------------

Univariate analysis was performed using Cox proportional hazards regression to identify the risk factors that were associated with OS and recurrence-free survival (RFS). All data were analyzed using the Statistical Package for Social Science software version 21.0 (SPSS, Chicago, IL, USA). For all analyses, *p* \< 0.05 was considered to be statistically significant.

Results {#Sec4}
=======

Patient Characteristics {#Sec5}
-----------------------

Patient characteristics are presented in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. In total, 10 patients, including nine males and one female, underwent hepatectomy for liver metastasis of gastric cancer. Synchronous and metachronous metastases were noted in four (40.0%) and six (60.0%) patients, respectively, whereas single and multiple liver metastases were found in seven (70.0%) and three (30.0%) patients, respectively. Tumor size was \> 3 cm in four (40.0%) patients, and two patients (20.0%) had new liver metastases after hepatic resection and underwent second hepatic resection.Table 1CharacteristicsVariableValueAge Median (range)68 (47--75) yearsSex Male9 (90.0%) Female1 (10.0%)Tumor size \< 5 cm6 (60.0%) ≧ 5 cm4 (40.0%)Histological type Intestinal6 (60.0%) Diffuse4 (40.0%)Lymphatic invasion ly 02 (20.0%) ly 1/2/38 (80.0%)Tumor invasion T0/T11 (10.0%) T2 SS2 (20.0%) T3 SE T4 SI7 (70.0%)Lymph node metastasis N0 + N17 (70.0%) N2 + N33 (30.0%)Metachronous/Synchronous Metachronous 6 (60.0%) Synchronous 4 (40.0%)Number of metastasis 17 (70.0%) 23 (30.0%)Number of hepatic surgery Once8 (80.0%) Twice 2(20.0%)Table 2Clinical and pathological dataPatientAgeSexDepth of tumorType of gastric cancerTumor size of gastric cancer \[cm\]Number of lymph node metastasisLevel of lymphoticLevel of venous invasionOperation typeTMNStage170MSSPoor2.5 × 2.52/2212Total gastrectomyT3N1M14255MSMMode2.5 × 2.50/1700Total with splenectomyT1bN0M01A369MMPMode2.5 × 2.22/1821Total with splenectomyT2N0M01B467MSSPapi5.7 × 5.70/2222Distal gastrectomyT3N0M02A565MMPWell2.3 × 2.32/2211Distal gastrectomyT2N1M02A647MSEPoor9.0 × 7.513/1632Distal gastrectomyT4aN3aM03C753MSSMode4.0 × 4.36/2322Distal gastrectomyT3N2M03A875MSSPoor3.0 × 3.50/202Completion gastrectomyT3N0M14975FSEWell10.0 × 6.57/2333Total gastrectomy with splenectomy and pancreatomyT4aN3aM141074MSEPoor5.0 × 5.02/1422Distal gastrectomyT4aN1M14PatientType of liver metastasisNumber of hepatic metastasisTumor size of hepatic meta \[cm\]Interval between operations \[month\]Operation typeSurvival time after hepatectomy \[month\]Survival statusNACAdjuvant1Syn11.512Partial11AliveSPTS-12Meta22.5, 0.633Partial33Death----3Meta12.536Partial33Death--TS-14Meta23, 47Partial26Death----5Meta14.559Segmentectomy39Death----6Meta1713Partial5Death--FU/LV7Meta147Segmentectomy205Alive--UFT8Syn10.80Enucleation62Death----9Syn21.6, 0.80Partial10Death--UFT10Syn110Partial33Death--UFT

Patient Outcomes {#Sec6}
----------------

Median age at the time of hepatic resection was 68 (range, 47--75) years. Patient outcomes are presented in Table [3](#Tab3){ref-type="table"}. Briefly, 1-, 3-, and 5-year OS rates after surgery were 78.0%, 33.3%, and 22.2%, respectively, with a median OS of 2.583 years. Additionally, 1-, 3-, and 5-year RFS rates were 44.4%, 22.2%, and 22.2%, respectively, with a median RFS of 0.792 years.Table 3Univariate analysisUnivariate analysis of hazard ratio estimated by Cox regression (OS/RFS)NumberHR95% CI*p*HR95% CI*p*Sex Female111 Male90.1180.007--1.8860.1310.4070.042--3.9310.437Age years \< 65311 ≧ 6571.4930.296--7.5290.6281.3450.264--6.8540.721Tumor size of primary cancer \< 5 cm611 ≧ 5 cm46.5241.145--37.1710.0353.2160.706--14.6490.131Histological type Intestinal611 Diffuse41.0840.256--4.5920.9130.7940.188--3.3560.754Lymphatic invasion ly0/ly1411 ly2/ly361.6360.384--6.9620.5051.6920.401--7.1490.474Venous invasion V0/V1311 V2/V370.9390.206--4.2880.9350.5550.123--3.5070.444Tumor invasion T0/T1/T2311 T3/T474.2880.849--21.6610.0782.2480.500--10.0970.291Lymph node metastasis N0411 N1/N2/N360.880.217--3.5660.8580.5590.136--2.2920.419Metachronous/synchronous Metachronous61 Synchronous40.980.231--4.1600.9781.3450.264--6.8540.721Number of metastasis 1811 223.3690.658--17.2370.1453.6090.592--22.0110.164Maximum size of the metastatic tumor \< 3 cm611 ≧ 3 cm40.8340.912--3.6260.8090.8310.201--3.6350.831Hepatic surgery Once811 Twice22.0020.362--11.0730.4261.4530.280--7.5490.657

There was a significant difference in OS between patients whose primary gastric cancer measured ≥ 5 cm and those whose primary gastric cancer measured \< 5 cm (hazard ratio \[HR\] 6.524, 95% confidence interval \[CI\] 1.145--37.171, *p* = 0.035). There was a trend towards a difference in OS rates between patients whose cancer depth was serosal exposure (SE) or serosal invasion (SI) and those whose cancer depth was shallower than SE (HR 4.288, 95% CI 0.849--21.661, *p* = 0.078).

Discussion {#Sec7}
==========

Despite improved postoperative outcomes in recent years \[[@CR15]\], survival rates of patients with liver metastasis of gastric cancer have not increased as much as those observed with hepatic resection for metastatic lesions of colon cancer \[[@CR12]--[@CR14]\]. Liver metastasis is an important point of consideration in treatment regimens for patients with gastric cancer \[[@CR16], [@CR17]\]. Compared with colon cancer, fewer patients with gastric cancer are candidates for hepatic resection as they often harbor multiple liver metastases as well as coexisting metastases in other locations.

Several recent studies on liver resection in gastric cancer reported that some patients achieved long-term survival of 2--6 years, with 1- and 5-year OS rates of 60--77% and 10--42%, respectively, and a median survival time ranging from 8.8 to 34 months; the findings of the current study are in agreement with these previous reports \[[@CR1]--[@CR11]\].

Among many studies investigating prognostic factors for liver resection in gastric cancer, several reported that single liver metastases and those measuring \< 5 cm were associated with good prognosis \[[@CR2]--[@CR5], [@CR9]\]. However, in the present study, the number of liver metastases and tumor were not associated with OS. Patients with single liver metastatic lesions died within a year, and there was only one patient whose tumor diameter was 5 cm. The patients in the present study were stratified according to a tumor diameter of 3 cm. Further analysis using a tumor diameter cutoff value of 4 cm did not reveal significant differences in OS rates between the groups (data not shown).

Our results suggest that primary gastric cancer invading deeper than submucosa may be a poor prognostic factor. Serosal invasion is a proposed mechanism of peritoneal seeding \[[@CR15]\], and some studies suggest that serosal invasion may be a poor prognostic factor for liver surgery \[[@CR8], [@CR10]\]. In the present study, there were two patients with primary gastric cancers that were not deeper than submucosa who survived for 33 and 39 months, respectively. Of the remaining eight patients, six (75%) died within 3 years of hepatic resection. The depth of primary gastric cancer should be considered as a prognostic factor in liver metastasis of primary gastric cancer.

Although several prognostic factors were reported to be associated with liver metastasis of primary gastric cancer, the size of primary gastric cancer was not previously reported as a significant predictor of favorable outcomes, which should be evaluated in future studies.

In the current study, two of the 10 patients underwent hepatic resection twice, and both survived for \> 2 years after the first hepatic resection, longer than the reported survival time. Surgery should be considered with consideration of the patient's clinical condition for recurrent liver metastasis following the first hepatic resection in patients with gastric cancer.

One major limitation of the present study is its retrospective design that involved a single institution; therefore, the number of patients was small, and only univariate analysis was performed. However, our cohort is similar to most studies on liver metastasis of gastric cancer which included a series of 10--20 patients at most, with a very limited number of larger cohorts available at this time. Despite the limited number of studies on hepatic resection of liver metastasis in gastric cancer, this approach was reported to be ineffective in certain patients. Therefore, future, large-scale studies are necessary to identify those patients who should undergo surgery.

Conclusion {#Sec8}
==========

Some of the patients undergoing hepatic resection for liver metastasis of gastric cancer achieved long-term survival. Primary tumor size was associated with long-term survival.
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